Evidence map›Paper›PMID 37936408›Full record

ArticleTherapeutic advances in respiratory disease

Clinical factors linked to the type of respiratory medication in COPD: results from the COSYCONET cohort.

Peter Alter, Kathrin Kahnert, Franziska C Trudzinski, Robert Bals, Henrik Watz, Tim Speicher, Sandra Söhler, Tobias Welte, Klaus F Rabe, Emiel F M Wouters and 2 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in respiratory disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01245933 (Impact of Systemic Manifestations/Comorbidities on Clinical State, Prognosis and Utilisation of Health Care Resources in Patients With COPD), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01245933 completednot on this map

Impact of Systemic Manifestations/Comorbidities on Clinical State, Prognosis and Utilisation of Health Care Resources in Patients With COPD

TypeobservationalSponsorPhilipps University MarburgRan2010 to 2023Enrolled2,741ConditionsChronic Obstructive Pulmonary Disease (COPD)
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Association of Obesity with Symptoms and Quality of Life in COPD: Results from COSYCONET.International journal of chronic obstructive pulmonary disease · 2025
    Observational
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 2 countries.

Peter AlterDepartment of Medicine, Pulmonary, Critical Care and Sleep Medicine, Philipps University of Marburg (UMR), Baldingerstrasse 1, Marburg 35033, Germany.ORCID 0000-0002-2115-1743
Kathrin KahnertDepartment of Medicine V, LMU University Hospital, LMU Munich, Comprehensive Pneumology Center, German Center for Lung Research (DZL), Munich, Germany.ORCID 0000-0001-9633-3368
Franziska C TrudzinskiDepartment of Pneumology and Critical Care Medicine, Thoraxklinik, University of Heidelberg, Translational Lung Research Center Heidelberg (TLRC-H), Center for Lung Research (DZL), Heidelberg, Germany.
Robert BalsDepartment of Internal Medicine V - Pulmonology, Allergology, Intensive Care Medicine, Saarland University Hospital, Germany.
Henrik WatzPulmonary Research Institute at LungenClinic Grosshansdorf, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Grosshansdorf, Germany.
Tim SpeicherDepartment of Medicine, Pulmonary and Critical Care Medicine, Philipps University of Marburg (UMR), Marburg, Germany.
Sandra SöhlerDepartment of Medicine, Pulmonary and Critical Care Medicine, Philipps University of Marburg (UMR), Marburg, Germany.
Tobias WelteClinic for Pneumology, Hannover Medical School, German Center for Lung Research (DZL), Hannover, Germany.
Klaus F RabeLungenClinic Grosshansdorf and Department of Medicine, Christian-Albrechts University, Kiel, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Grosshansdorf, Germany.ORCID 0000-0002-7020-1401
Emiel F M WoutersDepartment of Respiratory Medicine, Maastricht University Medical Centre, Maastricht, Netherlands and Ludwig Boltzmann Institute for Lung Health, Vienna, Austria.
Claus F VogelmeierDepartment of Medicine, Pulmonary and Critical Care Medicine, Philipps University of Marburg (UMR), Marburg, Germany.
Rudolf A JörresInstitute and Outpatient Clinic for Occupational, Social and Environmental Medicine, University Hospital, LMU Munich, Comprehensive Pneumology Center Munich (CPC-M), German Center for Lung Research (DZL), Munich, Germany.
German Center for Lung Research · DEPhilipps University of Marburg · DEHeidelberg University · DEMaastricht University Medical Centre · NLMedizinische Hochschule Hannover · DESaarland University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe use of maintenance medication in patients with chronic obstructive pulmonary disease (COPD) in real life is known to deviate from recommendations in guidelines, which are largely based on randomized controlled trials and selected populations.

objectivesWe used the COSYCONET (

designCOSYCONET is an ongoing, multi-center, non-interventional cohort of patients with COPD.

methodsPatients with COPD of Global Initiative for Chronic Obstructive Lung Disease (GOLD) grades 0-4 participating in visits 1-5 were included. Data covered the period from 2010 to 2018. Generalized linear models were used to examine the relation of COPD characteristics to different types of respiratory medication.

resultsA total of 1043 patients were included. The duration of observation was 4.5 years. Use of respiratory medication depended on GOLD grades 0-4 and groups A-D. Long-acting muscarinic antagonist therapy increased over time, and was associated with low carbon monoxide (CO) diffusing capacity, while inhaled corticosteroid (ICS) use decreased. Active smoking was associated with less maintenance therapy in general, and female sex with less ICS use. From the eight items of the COPD Assessment Test, only hill and stair climbing were consistently linked to treatment.

conclusionUsing data from a large, close to real-life observational cohort, we identified factors linked to the use of various types of respiratory COPD medication. Overall, use was consistent with GOLD recommendations. Beyond this, we identified other correlates of medication use that may help us to understand and improve therapy decisions in clinical practice.

trial registrationClinicalTrials.gov NCT01245933.

Indexed as

Adrenal Cortex HormonesPulmonary Disease, Chronic ObstructiveAdministration, InhalationAdrenergic beta-2 Receptor AgonistsBronchodilator AgentsComorbidityFemaleHumansMaleMulticenter Studies as TopicMuscarinic AntagonistsObservational Studies as TopicAdrenal Cortex HormonesAdrenergic beta-2 Receptor AgonistsBronchodilator AgentsMuscarinic Antagonistschronic obstructive pulmonary diseasecomorbiditiesGOLD categoriesmedication userespiratory medicationsymptoms

Identifiers

PMID37936408
PMCPMC10631320
OpenAlexW4388495128

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.